SciSparc Ltd. (NASDAQ:SPRC) Short Interest Update

SciSparc Ltd. (NASDAQ:SPRC) was the recipient of a significant decrease in short interest in August. As of August 14th, there was short interest totaling 17,206 shares, a decrease of 54.7% from the July 30th total of 37,966 shares. Based on an average daily volume of 92,075 shares, the short-interest ratio is currently 0.2 days. Currently, 3.1% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

SPRC has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SciSparc in a research report on Friday, August 21st. Wall Street Zen upgraded shares of SciSparc to a “hold” rating in a research note on Saturday, July 18th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

SciSparc Trading Down 0.6%

Shares of NASDAQ:SPRC traded down $0.04 during trading on Friday, reaching $6.58. 84,130 shares of the stock were exchanged, compared to its average volume of 75,983. SciSparc has a 12 month low of $2.98 and a 12 month high of $80.10. The stock has a 50-day moving average price of $6.04 and a 200-day moving average price of $5.83.

About SciSparc

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.